At a glance
ClinicalIndex Comparison Record- ✓Confirmed cancer diagnosis by biopsy or cytology
- ✓Presence of carcinomatous ascites
- ✓Age 20–80 years at time of informed consent
- ✓ECOG Performance Status 0–2 with ≥3 months survival expectancy
- ✕Active infection requiring systemic treatment
- ✕Deep vein thrombosis
- ✕Intestinal obstruction or intestinal edema with symptoms similar to intestinal obstruction
- ✕Hepatic cirrhosis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
1 article- #ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints News·2026-06-06
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)
In Brief
A Phase 2 clinical trial evaluating OPC-41061 for Carcinomatous Edema. Completed, enrolled 43 participants across 1 site.
Detailed Summary
OPC-41061 will be administered to patients with volume overload associated with cancer, first by dose-escalation and subsequently for 6 consecutive days at the fixed dose at which urine volume is increased to investigate efficacy, pharmacokinetics, pharmacodynamic effects, and safety and to determine the effective initial and maintenance doses of OPC-41061.
Study Details
Timeline
Interventions
orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.